Financial Performance - The company achieved a total sales revenue of 549 million yuan in 2022, representing a decrease of 6.04% compared to the previous year[5]. - The company's operating revenue for 2022 was ¥548,988,617.75, a decrease of 6.04% compared to ¥584,291,440.90 in 2021[28]. - The net profit attributable to shareholders for 2022 was -¥197,008,085.75, representing a decline of 43.38% from -¥137,400,196.24 in 2021[28]. - The basic earnings per share for 2022 was -¥0.41, down 41.38% from -¥0.29 in 2021[29]. - The total revenue for the company in 2022 was approximately ¥548.99 million, representing a decrease of 6.04% compared to ¥584.29 million in 2021[73]. - The main product, Su Tai Sheng, generated sales revenue of ¥174.02 million, accounting for 31.70% of total revenue, with a year-on-year decline of 3.73%[67]. - The company's other main product, Shu Tai Qing, achieved sales revenue of ¥365 million, making up 66.43% of total revenue, which is an 8.47% decrease from the previous year[67]. - The company reported a total revenue of 1.2 billion RMB for the fiscal year 2022, representing a year-over-year increase of 15%[179]. - The company reported a net profit of 416 million RMB, representing a growth of 156.49% year-over-year[173]. Research and Development - Research and development expenses for the year amounted to 363 million yuan, which is an increase of 0.08% year-on-year[5]. - The company plans to sustain a high level of R&D investment in the near future due to the ongoing progress of its research projects[6]. - The company’s R&D pipeline includes protein drugs, gene therapy/cell therapy drugs, and chemical drugs, targeting unmet clinical needs in infectious diseases, autoimmune diseases, and neurological disorders[42]. - The company has multiple I class innovative biopharmaceuticals in clinical trial stages, including BDB-001, STSA-1002, STSA-1005, STSP-0601, and STSG-0002, with ongoing research in areas such as neurological diseases, infectious diseases, and autoimmune diseases[52]. - The company has developed a leading new drug R&D technology platform, including various advanced screening and production systems, to support its innovative drug development[58]. - The company is focusing on accelerating the progress of its R&D projects, particularly those in Phase I and II/III clinical trials, to advance them to the next stages[120]. - The company has allocated 60 million RMB for research and development in the upcoming fiscal year, a 15% increase from 2022[175]. Market Strategy and Expansion - The company emphasizes a strategy of innovation-driven development and aims to enhance its marketing capabilities to support ongoing research projects[6]. - The company is exploring new project launches through acquisitions and collaborative development to expand its research pipeline[7]. - The company plans to expand its market presence in the constipation-related market based on its success in the bowel cleansing sector[41]. - The company plans to expand its market presence in Southeast Asia, targeting a 20% market share by 2025[174]. - The company is exploring partnerships with international firms to broaden its distribution network, aiming for a 25% increase in international sales[179]. - The company is actively involved in technology development, transfer, and consulting services, which are key components of its business model[118]. Governance and Compliance - The company has established a comprehensive governance structure to ensure effective decision-making and supervision[130]. - The company emphasizes strict compliance with information disclosure regulations, designating the chairman as the primary responsible person for information disclosure[138]. - The board of directors consists of seven members, including three independent directors, and all directors actively participated in relevant training to enhance their capabilities[135]. - The company has established specialized committees under the board, including the Strategy, Nomination, Audit, and Compensation Committees, to enhance governance and decision-making[162]. - The company has maintained effective communication with investors through various channels, enhancing investor relations management[138]. Financial Management - The company has implemented cost-control measures that are expected to reduce operational expenses by 5% in the next year[174]. - The total remuneration paid to the current directors, supervisors, and senior management in 2022 amounted to RMB 10.2585 million and USD 150,000[190]. - The company has committed to improving its internal control systems and management capabilities to adapt to its expanding operational scale[125]. - The company has ensured timely, accurate, and complete disclosure of the use of raised funds, with no violations in fund management and disclosure[104]. Challenges and Risks - The company reported a net profit of negative value for the reporting period, indicating ongoing short-term performance pressure[5]. - The pharmaceutical industry faces challenges from external policies such as centralized procurement and medical reform, impacting production and sales[6]. - The company acknowledges the inherent risks in drug development, including high investment and long development cycles, which may affect profitability[7]. - The company faces risks related to the development and market acceptance of innovative drugs, which may impact its business and financial status[122]. - The company is addressing the risk of talent shortages by improving its human resource management system and establishing an employee equity incentive plan[123].

证券代码：300204 证券简称：舒泰神 公告编号：2023-11-16 舒泰神（北京）生物制药股份有限公司 关于举行 2022 年度业绩网上说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 舒泰神（北京）生物制药股份有限公司（以下简称"公司"）已于 2023 年 03 月 21 日披露了公司 2022 年年度报告。为便于广大投资者更深入、全面地了解公 司发展战略、生产经营等情况，公司定于 2023 年 04 月 07 日（星期五）下午 15:00 －17:00 举办 2022 年度业绩说明会，本次年度业绩说明会将采用网络远程的方式 举行，投资者可登录全景网"投资者关系互动平台"（http://rs.p5w.net）参与本次 年度业绩说明会。 出席本次年度业绩网上说明会的人员有：董事长周志文先生、总经理王超先 生、董事会秘书兼副总经理于茂荣先生、独立董事孙英女士。 欢迎广大投资者积极参与。 特此公告 舒泰神（北京）生物制药股份有限公司 董事会 2023 年 03 月 20 日 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 ...

Group 1: Company Overview - Staidson (Beijing) Biopharmaceutical Co., Ltd. is identified with the stock code 300204 and the abbreviation Shutaishen [1] Group 2: Investor Relations Activity - The investor relations activity recorded was a specific object investigation conducted on October 24, 2014 [2] - Participating units included Huachuang Securities and Liuhe Investment [2] - The meeting was held in the company conference room, hosted by Marina [2] Group 3: Main Content of the Activity - The main topics discussed included sales situation, product status, and investment acquisition [2]

Group 1: Market Competition and Product Positioning - The sales of nerve injury repair drugs have maintained a rapid compound growth, with mouse nerve growth factor having a small market share due to late market entry and fewer manufacturers [1] - Among four domestic mouse nerve growth factor products, Sutai Shen's Sutai Sheng holds the leading market share [1] - Competition in the market is present but also signifies joint development and expansion of market share [1] Group 2: Sales Growth and Product Guidelines - Sutai Qing is currently the preferred medication for constipation in clinical guidelines, contributing to its rapid sales growth [1] - The company aims to continuously enhance sales revenue from Sutai Qing [1] Group 3: Investment and R&D Focus - The company is actively seeking domestic and international investment and acquisition opportunities for promising products or companies [2] - R&D investment is closely linked to project progress, with a strong emphasis on innovative R&D and maintaining a competitive environment for talent [2][3] - The company is developing a human nerve growth factor using recombinant gene technology, which offers advantages in homology compared to mouse nerve growth factor [2] Group 4: Financial Management and Incentives - The stock incentive expenses have been fully accounted for, with no further issues expected in the second half of the year [2] - Future consideration for a new stock incentive plan is planned [2] - Sales expense ratio is expected to remain stable [3]

证券代码：300204 证券简称:舒泰神 舒泰神（北京）生物制药股份有限公司 投资者关系活动记录表 编号：2015-004 | --- | --- | --- | |--------------|--------------------------|--------------------------------------------------| | | | | | 投资者关系活 | ■ 特定对象调研 | □ 分析师会议 | | 动类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称 | 国泰君安、民生证券 | | | 时间 | 2015 年 08 月 25 | 日 | | 地点 | 公司会议室 | | | 上市公司接待 | | | | 人员姓名 | 马莉娜 | | | 投资者关系活 | | 公司经营情况、研发情况、投资德丰瑞概况、公司产品 | | 动主要内容介 | 情况等。 | | | 绍 | | | | 附件清单 | 调研纪要 | | | 日期 | 2015 年 08 月 25 | 日 | ...

Financial Performance - The company achieved total revenue of CNY 55,904.30 million in the first half of 2015, representing a year-on-year growth of 12.26% [2] - The net profit attributable to shareholders was CNY 10,929.33 million, marking an impressive increase of 80.90% compared to the same period last year [2] Marketing Strategy - The company has strengthened its market efforts, focusing on bidding and price maintenance across provinces, with successful bids and a controlled price reduction [2] - The sales team has improved efficiency through training and skill enhancement [2] Research and Development - The company is focused on market-driven new product development and improving R&D efficiency [2] - A knowledge property team is being established to support innovation and protect intellectual property [2] Market Competition - The market for nerve injury repair drugs is growing rapidly, with the company's product, Su Tai Shen, holding the largest market share among four competitors [3] - The company aims to expand its market share by leveraging the advantages of its products [3] Investor Insights - The company is considering a new equity incentive plan in the future [3] - The impact of medical insurance cost control is recognized as a long-term challenge, with strategies to adapt and enhance sales in smaller hospitals [3] Product Development - The company has invested CNY 50 million in Beijing Defengrui Biotechnology Co., which holds exclusive rights to develop and sell monoclonal antibody drugs in China [4] - The project is expected to enhance the company's competitive edge and improve investment returns [4] Hospital Coverage - The target is to cover approximately 8,000 hospitals, with 2,200 currently developed, focusing on secondary and tertiary hospitals [5] - The company plans to increase its presence in county-level hospitals [5] Product Applications - Su Tai Qing, aimed at treating constipation and bowel cleansing, has a market potential of approximately CNY 800 million [5] - The product is safe and effective for various patient groups, including the elderly and pregnant women [5] Market Potential for OAB - The global market for overactive bladder (OAB) drugs was valued at USD 2.724 billion in 2013, with a projected annual growth rate of 4% [8] - The estimated market potential in China for OAB treatment is around CNY 13.8 billion annually [8] Competitive Advantages - The company's product, Qusi Luan, is recognized for its strong efficacy and minimal CNS side effects, making it a leading M receptor antagonist [9] - It is the only M receptor antagonist that does not undergo liver enzyme metabolism, with no reported drug interactions [10]

Group 1: Company Overview - Company Name: Shuotai Shen (Beijing) Biopharmaceutical Co., Ltd. [2] - Stock Code: 300204 [1] - Stock Abbreviation: Shuotai Shen [1] Group 2: Investor Relations Activity - Activity Type: Specific Object Research [2] - Date of Activity: November 6, 2014 [3] - Location: Company Conference Room [2] Group 3: Participants - Participating Institutions: Huashang Fund, Xinhua Asset, CITIC Securities, Dongxing Securities, and others [2] - Notable Participants: Individual investors and various funds [2] Group 4: Discussion Topics - Main Content of Discussion: Sales situation, R&D status, product situation, equity incentive situation, acquisition status, etc. [2]

Financial Performance - The company achieved total revenue of 78,962.66 million yuan in the first three quarters of 2014, representing a year-on-year growth of 21.95% [2] - The net profit attributable to shareholders was 12,357.58 million yuan, reflecting a year-on-year increase of 7.65% [2] Marketing Strategy - The company has tailored product planning and academic promotion strategies based on market research, enhancing brand building [2] - Training and improvement of sales personnel's capabilities have increased overall sales team efficiency [2] - The company is optimizing sales channels to consolidate existing markets while actively exploring potential markets [2] Research and Development - Key R&D projects are progressing, with improvements in organizational structure and innovation environment [2] - The company is focusing on enhancing R&D efficiency [2] Product Performance - Sales of the product "Sutai Sheng" have increased by over 15% year-on-year [4] - The product is performing well in provinces such as Zhejiang, Guangdong, Beijing, Shanghai, and Shaanxi [4] - "Sutai Sheng" holds the largest market share among nerve injury repair drugs, despite competition [4] Competitive Landscape - The market for nerve injury repair drugs is experiencing rapid compound growth, with "Sutai Sheng" benefiting from its effectiveness and fewer side effects [4] - The product is recognized for its direct repair action on nerve damage, distinguishing it from other neuroprotective agents [4] Regulatory and Clinical Guidelines - "Shutai Qing" is included as a first-choice medication in clinical guidelines for constipation [5] - The product is deemed safe and effective for various demographics, including the elderly, pregnant women, and children [6] Future Considerations - The company is considering new stock incentive plans after completing the current stock incentive expense [7] - There is an ongoing search for promising products or companies for potential acquisition [7] Sales Model - The marketing model for "Sutai Sheng" primarily employs a self-operated plus招商 (investment attraction) approach [7] - "Shutai Qing" also utilizes a similar sales model, with significant contributions from self-operated sales [7]